Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2025 was €186.08 Mil.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-EBIT Related Terms
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-EBIT Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Enterprise Value is €597.56 Mil.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a EV-to-EBIT of -30.63 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EV-to-EBIT is -30.63. Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #999999 out of 692 companies for EV-to-EBIT. This places Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current EV-to-EBIT is -30.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current EV-to-EBIT of -30.63. The stock's GF Value™ is €0.23, compared to a current price of €0.26 — trading 13.9% above its estimated fair value. The current EV-to-EBIT is -30.63. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current EV-to-EBIT is -30.63 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of €0.26 is trading 13.9% above its estimated GF Value™ of €0.23.
Key valuation signals for FRA:FDY:
EV-to-EBIT: -30.63
GF Value™: €0.23 vs. price of €0.26 (13.9% above fair value)
No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score
Get the complete analysis for FRA:FDY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FDY has been successfully added to your 
